secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001372514-24-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track
--------------------------------------------------------------------------------

- Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.
- Revenue $16M from Théa Open Innovation upfront; net income $13.5M vs. $1.9M loss YoY.
- Phase 2 ABACUS-2 trial for KIO-301 (retinitis pigmentosa) on track for Q4 2024 start.
- Phase 2 trial for KIO-104 (retinal inflammation) expected to begin in 2025.
- TOI deal includes up to $285M milestones and tiered royalties up to low-20% on sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000054/0001372514-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000054/kprx-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer